CAJ | 학술논문

目的探讨p63和survivin在弥漫大B细胞淋巴瘤(DLBCL)中的表达及临床意义.方法采用免疫组织化学染色法检测p63蛋白和survivin蛋白在52例DLBCL和10例反应性增生淋巴结石蜡标本中的表达.结果 p63、survivin在DLBCL中表达阳性率分别为63.5%(33例)和76.9%(40例),p63在反应性增生淋巴结中呈阴性表达,survivin在反应性增生淋巴结中阳性率为20.0%(2例),p63和survivin的表达率在两组之间差异有统计学意义.p63、survivin阳性组患者复发率分别为68.0%和71.4%,高于阴性组的22.2%和30.8%.p63、survivin阳性组患者平均生存期分别为18.5个月和17.5个月,低于阴性组的29.0个月和30.3个月.结论 p63和survivin可作为DLBCL的疗效和预后指标,可在早期筛选出常规治疗预后不良的病例,有助于指导临床治疗,改善预后.
목적 탐토p63화survivin재미만대B세포림파류(DLBCL)중적표체급림상의의.방법 채용면역조직화학염색법검측p63단백화survivin단백재52례DLBCL화10례반응성증생림파결석사표본중적표체.결과 p63、survivin재DLBCL중표체양성솔분별위63.5%(33례)화76.9%(40례),p63재반응성증생림파결중정음성표체,survivin재반응성증생림파결중양성솔위20.0%(2례),p63화survivin적표체솔재량조지간차이유통계학의의.p63、survivin양성조환자복발솔분별위68.0%화71.4%,고우음성조적22.2%화30.8%.p63、survivin양성조환자평균생존기분별위18.5개월화17.5개월,저우음성조적29.0개월화30.3개월.결론 p63화survivin가작위DLBCL적료효화예후지표,가재조기사선출상규치료예후불량적병례,유조우지도림상치료,개선예후.
Objective To investigate the expression and significance of survivin and p63 in diffuse large B-cell lymphoma (DLBCL). Methods Immunohistochemical staining was used to detect the expression of survivin and p63 in the lymphnode tissues from DLBCL patients and lymph node reactive proliferation.Results The positive expression rate of p63 and survivin proteins in DLBCL patients was 63.5 %(33/52) and 76.9 %(40/52), respectively. p63 was not expressed in lymph node reative proliferation. The positive expression rate of survivin in lymph node reactive proliferation was 20.0 %. The expression rates of survivin and p63 between two groups was significant different. The replase rate of groups with positive expression of survivin and p63 were higher than that of the negative groups. The mean survival in groups with positive expression of survivin and p63 were shorter than that of the negative groups. Conclusion Survivin and p63 are useful in therapeutic and prognostic assessment. Patients with poor prognostic can be screened out in the early period of treatment using expression of survivin and p63, which may help to improve the outcome of diffuse large B-cell lymphoma.